NIHR Manchester Clinical Research Facility (CRF) is supporting research to enable more cancer patients in Wigan to receive new experimental treatments. 

The new study supported by the CRF is being delivered as part of a strategic partnership between The Christie and Wrightington, Wigan and Leigh NHS Foundation Trust. 

It is designed to test whether a medical device that delivers radiotherapy directly to the liver, used in combination with second-line chemotherapy is safe and can extend survival time.  Patients on the trial are attending research clinics at the CRF.

By sharing information about cancer research studies taking place in Greater Manchester, the strategic partnership enables clinicians at Wigan Infirmary to identify patients who may be suitable.  Those patients who choose to take part then receive care at either Wigan or The Christie’s specialist facilities, depending on the nature of the treatment.

The CRF provides the dedicated space and expertise required to deliver intensive and complex studies in a safe environment.

The CRF’s involvement in this partnership supports its strategic goal to provide more opportunities for patients who live outside of Central and South Manchester to take part in research. 

Professor Andrew Wardley, Clinical Director of the CRF at The Christie explains: “Last year over 40,000 people took part in clinical research studies across Greater Manchester1.  Historically the majority of people involved in CRF studies have lived close to our sites, generally in more affluent areas of Manchester.

Over the next five years, we aim to increase both the number of people taking part in research studies at our CRF and attract participants from other parts of the Greater Manchester area, which is where the Wigan collaboration fits in.” 

The CRF at The Christie is one of four specialist units in Manchester for experimental research that make up the NIHR Manchester CRF, with others at Manchester Royal Infirmary, Royal Manchester Children’s Hospital and Wythenshawe Hospital.